Table 2.
Characteristics of the included studies.
| Characteristics of Included Studies | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Reference (Localization) |
Age (years) (Mean ± SD) |
Subjects/Males (n) | Healthcare Setting | Pressure Ulcers at the Beginning of the Study SG/CG (n) | Healed Pressure Ulcers SG/CG (n) | Healed Pressure Ulcers (n)/A Total Number of Pressure Ulcers (n) | Length of Follow up | Source of Funding | The Types of Dressings | |
| SG | CG | ||||||||||
| 1. | Bale et al., 1997 (the UK) |
nd (median: SG: 74; CG: 73) | 60/27 | 5 centers in the UK | 31/29 | 5/7 | 12/60 | Up to 4 weeks (30 days). | Financial support from Smith and Nephew—industry funded. | A hydrocolloid dressing | A polyurethane foam dressing |
| 2. | Brown-Etris et al., 2008 (the USA, Canada) |
SG: 72.7 (18.6); CG: 78.3 (14.7) |
72/32 | A variety of healthcare settings, including extended-care facilities, outpatient wound care clinics, and home care agencies | 37/35 | 22/21 | 43/72 | Up to 8 weeks (56 days). | Grant from 3M Company (manufacturers of Tegaderm)—industry funded. | A hydrocolloid dressing (DuoDERM CGF, ConvaTec, ER Squibb & Sons, Princeton, NJ) | A transparent absorbent acrylic dressing (3M Tegaderm Absorbent Clear Acrylic Dressing) |
| 3. | Chamorro et al., 2019 (Spain) | SG: 83.3 (8.7); CG: 79.2 (13.3) |
169/71 | Primary care centers and ling-term care institutions | 85/84 | 54/69 | 123/169 | Up to 8 weeks | Grant from the Ministry of Economy and Competitiveness, Carlos III Institute (ISCIII), as well as with financial support from the Health Promotion and Preventive Activities- Primary Health Care Network, the Ministry of Health ISCIII-RETIC), and the European Union Regional Development Funds – non-industry funded. | A hydrocolloid dressing (VARIHESIVE® GEL CONTROL (Convatec) | A hydrocellular dressing (ALLEVYN Adhesive® (Smith & Nephew) |
| 4. | Gorse et al., 1987 (the USA) |
SG: 72.0 +/− 12.8; CG: 68.4–13.5 | 52/52 | The Huntington Veterans Administration Medical Center—acute-care facility | 76/52 | 54/26 | 80/128 | Approx. 11 weeks. | nd | A hydrocolloid dressing (Duoderm, Convatec, E.R. Squib and Sons Inc.) | A mesh-gauze wet-to-dry dressing (WDDs) |
| 5. | Hollisaz et al., 2004 (Iran) |
36.64 ± 6.04 | 83/83 | Family homes or nursing homes | 31/30 | 23/8 | 31/61 | Approx. 8 weeks (2 months). | Grant from the Jaonbazan Medical and Engineering Research Center, the medical and research section of the official governmental body responsible for spinal cord injury (SCI) war victims—non-industry funded. | A hydrocolloid dressing | A simple dressing |
| 6. | Hondé et al., 1994 (France) |
general—82 yearsSG: 83.5 +/− 7.8 (years 64–101); CG: 80.4 +/− 8.2 (years 63-98); | 168/47 | Geriatric hospital wards | 88/80 | 23/31 | 54/168 | Up to 8 weeks. | Financial support from Synthelabo Recherche (manufacturers of Inerpan)—industry funded. | A hydrocolloid dressing, Comfeel™ (Coloplast) | A copolymer membrane, Inerpan™ (Synthélabo) |
| 7. | Sopata et al., 2002 (Poland) |
general: 58.6 +/− 15.51; SG: 58.7 +/− 14.11; CG: 58.5 +/− 16.92 |
34/16 | Palliative Care Department at the University of Medical Sciences, Poznan, Poland | 17/17 | 15/15 | 30/38 | Up to 8 weeks. | This study was non-industry funded—declaration of interest: none. | A hydrogel dressing (Aquagel, Wytwórnia Opatrunków, Poland) | A polyurethane foam dressing Lyofoam (Seton, UK) |
| 8. | Thomas et al., 2005 (the USA) |
General—75.5 +/− 12.6; SG: 77.0 +/− 11.5; CG:74.1 +/− 13.8 |
41/21 | Outpatient clinics, long-term care nursing homes, and a rehabilitation center | 20/21 | 7/8 | 15/41 | Up to 12 weeks | nd | A sterile control hydrocolloid dressing (Duoderm™ Convatec, Inc., Princeton, NJ) with or without a calcium alginate filler (Sorbasan,™ Smith-Nephew, Inc., Largo, FL) | A radiant-heat dressingdevice (Warm-Up™, Augustine Medical, Inc., Princeton, NJ) |
Note: nd—no data; SG—study group; CG—control group; source: the authors’ own analysis.